TL;DR
BPC-157 is a synthetic 15-amino-acid research peptide studied mainly in rodents. Animal and cell research has explored blood-vessel formation, nitric-oxide signalling and tissue repair, but convincing human trials have not confirmed those findings. Public human evidence is sparse, and there is no established clinical safety or efficacy profile. Its popularity is well ahead of the quality of the evidence.
Evidence at a glance
| Type of evidence | What exists (as reviewed for this guide) |
|---|---|
| Animal and cell studies | More than 100 papers, most from one research group in Zagreb. Mainly rats. |
| Phase III human trials | None published in peer-reviewed literature. |
| Phase II human trials | A small number reported, mainly for inflammatory bowel disease. Full datasets and independent replication are not public. |
| Human safety profile | Not established. No human pharmacokinetic or dose-response data. |
| Status in Ireland | Not an authorised medicine. Not assessed by the EMA. |
What Is BPC-157?
BPC-157 — short for Body Protection Compound 157 — is a synthetic pentadecapeptide consisting of 15 amino acids. It was derived from a partial sequence of a protein found in human gastric juice and has been studied primarily in rodent models since the early 1990s, largely through the research group of Dr. Predrag Sikiric at the University of Zagreb.
The compound does not occur naturally in this exact form; it is a stable analogue engineered to resist degradation in the gastrointestinal environment. That stability is one reason it attracts research interest — it can retain biological activity when administered via multiple routes, including orally and systemically.
BPC-157 is classified as a research chemical and has never progressed to approved Phase III clinical trials in humans. All evidence discussed in this article is drawn from preclinical animal models unless otherwise stated.
How does BPC-157 work?
Researchers have proposed several overlapping pathways through which BPC-157 may exert its observed effects in animal models. The three most studied are:
1. Angiogenesis Promotion
BPC-157 appears to upregulate the expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR2), stimulating the formation of new blood vessels in damaged tissue. Enhanced vascularisation is thought to accelerate nutrient and oxygen delivery to injury sites, which may explain observations of faster tissue repair in rodent tendon and muscle models.
2. Nitric Oxide Modulation
The compound interacts with the nitric oxide (NO) system, both endothelial (eNOS) and inducible (iNOS) pathways. Modulation of NO signalling affects vasodilation, inflammation signalling, and cellular survival responses. Some researchers propose this pathway underpins BPC-157's observed gastroprotective and anti-ulcer effects in animal studies.
3. Growth Hormone Receptor Interaction
BPC-157 appears to interact with the growth hormone (GH) receptor pathway, potentially enhancing tissue responsiveness to GH signalling. This has been proposed as a contributing mechanism to observed improvements in bone and tendon healing in rodent models, though the precise receptor binding kinetics in humans remain uncharacterised.
Note on mechanisms: Most mechanistic data comes from in vitro cell studies and rodent models. Whether these mechanisms translate to humans at physiologically relevant concentrations has not been established in controlled human trials.
What Animal Research Shows
The preclinical literature on BPC-157 is substantial — more than 100 papers, the majority from a single research group. Key areas of investigation include:
| Research Area | Observations in Animal Models |
|---|---|
| Tendon & Ligament Healing | Accelerated histological recovery in transected Achilles tendon and medial collateral ligament models in rats; increased collagen organisation and tensile strength at injury sites. |
| Gut Healing | Consistent gastroprotective effects against NSAID-, alcohol-, and stress-induced ulceration in rats; accelerated healing of intestinal fistulas and anastomoses in surgical models. |
| Neuroprotection | Reduction in lesion volume and improved motor recovery in rat models of traumatic brain injury and spinal cord damage; proposed mechanism via NO and dopamine pathway modulation. |
| Anti-inflammatory Effects | Reduction in inflammatory cytokine expression (TNF-alpha, IL-6) in multiple injury models; attenuated oedema in paw swelling assays. |
| Muscle & Bone | Enhanced bone density and callus formation in fracture models; improved muscle-to-bone reattachment in surgical transection studies. |
These findings are reproducible within specific laboratory conditions, but they come almost exclusively from rats and mice. Species differences in pharmacokinetics, receptor density, and healing biology mean extrapolation to humans requires significant caution.
Current State of Human Research
This is the most important section of this guide for anyone conducting serious research review: human clinical evidence for BPC-157 is extremely limited.
As of June 2026, no completed Phase III randomised controlled trials of BPC-157 have been published in peer-reviewed literature. There are a small number of reported Phase II trials — primarily for inflammatory bowel disease — but full datasets and independent replication are not available in the public domain.
What exists is:
- An extensive body of rodent and in vitro data — not human evidence
- Anecdotal reports in online communities — not scientific evidence
- Preliminary safety signals from small open-label studies — insufficient for conclusions
- No established human pharmacokinetic profile, bioavailability data, or dose-response curve
The gap between what animal models suggest and what has been demonstrated in humans is significant. Research communities and regulatory bodies consistently note this distinction. Anyone evaluating BPC-157 should weigh the preclinical data as hypothesis-generating, not as proof of efficacy or safety in humans.
Why BPC-157 Is Popular in Ireland's Fitness Community
Despite the limited human evidence, BPC-157 has achieved notable circulation in Irish gym and performance communities — particularly among athletes in strength sports, martial arts, and endurance training. Several factors contribute to this:
- Recovery narrative: The injury-healing research, though preclinical, maps directly onto common training injuries — tendinopathies, ligament strains, and overuse conditions that athletes want to address quickly.
- Perceived safety profile: The absence of commonly observed acute toxicity in animal studies at research doses, combined with the gastric origin of the parent protein, leads many to perceive it as low-risk. This perception is not supported by adequate human safety data.
- Online information spread: Forums, podcasts, and social media have amplified anecdotal reports, sometimes framing them as evidence of efficacy.
Understanding the community context helps explain the popularity, but it does not validate the underlying assumption that animal research translates to equivalent human outcomes.
Why I looked into it: I looked into BPC-157 because of a long-standing shoulder problem, which is the same reason a lot of people in Irish gyms ask about it. What I found is this page: strong rat data and almost no human data. That is not a recommendation, and nothing here suggests anyone should use it. Keith O’Beirne
How BPC-157 Was Given in Studies
Most animal studies gave BPC-157 by injection, under the skin or into the abdomen. Some tested it by mouth, mainly for gut outcomes, because it is unusually stable in stomach acid. How well either route works in people has not been measured. This page does not cover preparation, doses or administration.
What Quality Testing Can and Cannot Show
BPC-157 is sold as a research chemical in a largely unregulated market, and quality varies. Analytical reports are the only window into what a batch contains, and each test answers a narrow question:
- HPLC purity: how much of the sample is the target peptide versus other material. It does not confirm identity on its own.
- Mass spectrometry: whether the molecular weight matches the expected BPC-157 value. It supports identification, but a matching weight alone does not establish the sequence, and it says nothing about purity or safety.
- Endotoxin and sterility testing: contamination markers. A purity figure says nothing about these.
- Batch specificity: a report covers one batch or lot. It does not establish the next one.
None of these tests makes a research chemical safe for people. They describe a sample, not what it does in a human body.
Legal Status in Ireland
BPC-157 occupies a regulated but not explicitly prohibited position in Irish law, with important nuances:
- Not approved for human use: The HPRA has not authorised BPC-157 as a medicinal product. Advertising unauthorised human medicines is prohibited; supply and import are subject to legal restrictions.
- Research use: Possession and use for genuine laboratory research purposes is not prohibited, provided the compound is not being sold or supplied for human administration.
- Not a controlled substance: BPC-157 is not listed under the Misuse of Drugs Act in Ireland as of the publication date of this article. This may change as regulatory frameworks evolve globally.
- Anti-doping: BPC-157 is named on the WADA 2026 Prohibited List under S0, non-approved substances, and is prohibited at all times. Athletes subject to testing should treat it as banned.
- EU position: The EMA has not evaluated BPC-157. Importing unauthorised medicines into Ireland is restricted, so do not assume any import route is legal; check current HPRA and Revenue guidance.
Regulatory positions can change. Always verify current HPRA guidance directly at hpra.ie for the most up-to-date status.
Common questions
What does BPC-157 do?
In rat studies, BPC-157 was linked to faster tendon, gut and muscle repair. Human trials have not confirmed any of this, and there is no established human safety profile.
Is BPC-157 legal in Ireland?
BPC-157 is not an authorised medicine in Ireland. Advertising unauthorised human medicines is prohibited; supply and import are subject to legal restrictions. Check current HPRA and Revenue guidance. It is not listed under the Misuse of Drugs Act as of this guide.
Is there human evidence for BPC-157?
Very little. No Phase III trials have been published, and the few reported Phase II trials have no public full datasets or independent replication.
Is BPC-157 banned in sport?
Yes. WADA's 2026 Prohibited List names BPC-157 under S0 (non-approved substances), prohibited at all times, in and out of competition. Athletes who are tested should treat it as banned.
References
- Sikiric P, Separovic J, Anic T, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris. 1999;93(6):479–485. doi:10.1016/S0928-4257(99)00123-0.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126–1135. doi:10.2174/13816128113190990411.
- Seiwerth S, Brcic L, Batelja Vuletic L, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121–1125. doi:10.2174/13816128113199990421.
Keep reading
The peptide hub explains Irish legal status and how to judge peptide evidence. For something with strong human evidence behind it, start with protein and training.